ARCA biopharma, Inc. (ABIO)
After hours:
| Previous Close | 2.2500 |
| Open | 2.2800 |
| Bid | 2.2400 x 1000 |
| Ask | 2.2500 x 800 |
| Day's Range | 2.1800 - 2.3280 |
| 52 Week Range | 2.1700 - 5.5000 |
| Volume | |
| Avg. Volume | 412,712 |
| Market Cap | 32.423M |
| Beta (5Y Monthly) | 2.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6910 |
| Earnings Date | Aug. 03, 2021 - Aug. 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potenti
- Simply Wall St.
ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week
It might be of some concern to shareholders to see the ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price down 20% in...
- GlobeNewswire
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Tom Keuer, Chief Operating Officer, will present at the Q4 Virtual Investor Summit being held November 16-17, 2021. ARCA is scheduled to present on Wednesday, November 17, 2021 at 4:15 PM ET. Management will be available for one-on-one meetings to
